Ogden Christopher 4
4 · CytomX Therapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
CytomX (CTMX) CFO Christopher Ogden Sells Shares
What Happened Christopher Ogden, Chief Financial Officer of CytomX Therapeutics, sold 1,624 shares on 2026-06-15 at $3.05 per share, generating proceeds of $4,953. The Form 4 states the shares were sold solely to satisfy tax or other government withholding obligations in connection with RSU vesting.
Key Details
- Transaction date & price: 2026-06-15 — 1,624 shares sold at $3.05 each (total $4,953).
- Transaction code: S (sale); footnote F1: sale solely for tax/government withholding on RSU vesting.
- Shares owned after transaction: filing notes inclusion of 167,249 RSUs (footnote F2).
- Filing date/timeliness: Form filed 2026-06-17 — within the typical 2-business-day window (timely).
Context This was a tax-withholding sale tied to RSU vesting, a routine administrative transaction that doesn’t necessarily signal a change in the insider’s view of the company. For investors, outright purchases by insiders are generally more notable than routine sales for tax purposes.
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-06-15$3.05/sh−1,624$4,953→ 295,324 total
Footnotes (2)
- [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F2]Includes 167,249 RSUs.
Signature
/s/ Christopher Ogden|2026-06-17